ERBB2 and breast cancer: A recent meta-analysis has confirmed that the efficacy of highly toxic anthracyclines in early breast cancer is limited to women with HER2 (ERBB2) amplification or overexpression [1] and EGFR copy number holds promise in predicting response to the expensive monoclonal cetuximab, in contrast to the apparent failure of immunohistochemical staining for EFGR [2].